Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients

被引:11
|
作者
Czarnecka, D. [1 ]
Koch, E. M. W. [1 ]
Gottwald-Hostalek, U. [1 ]
机构
[1] Merck KGaA, D-64293 Darmstadt, Germany
关键词
Adherence; Amlodipine; Antihypertensive therapy; Bisoprolol; Fixed-dose combination; SAFETY;
D O I
10.1185/03007995.2015.1027676
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The study objective was assessing patient adherence to a fixed-dose combination (FDC) of bisoprolol and amlodipine in daily practice in patients who had been switched from the free to the fixed-dose combination prior to recruitment. Material and methods: The non-investigational study was carried out in Poland. Patients over 18 years of age with essential hypertension were recruited if they had already been switched from a free combination to the FDC at least 4 weeks prior to recruitment. Exclusion criteria included pregnancy, lactation, any contraindication to the FDC, and other antihypertensive treatment. Adherence was measured by tablet count (tablets taken divided by tablets prescribed, times 100) and defined as follows: excellent >90%, good 76-90%, moderate 51-75%, bad <= 50%. Other patient data, clinical findings and laboratory values were recorded upon availability at study start, after 3 months (voluntary) and after 6 months. Results: Data of 4288 patients (mean age: 59 years; gender: 50% each) were documented. The average daily doses of the FDC were 5.8 mg bisoprolol and 6.4 mg amlodipine. These doses differ only slightly from those of the free combination. After 3 months' treatment with the FDC, a dose increase was carried out in 113 patients for bisoprolol and in 126 for amlodipine. After 6 months of FDC treatment, 82% of the participants of the study showed excellent adherence and for a further 15% the adherence could be considered good. This strong adherence may have led to the observed reduction in systolic and diastolic blood pressure of 11% (Cohen's D efficient size 1.23). In addition, pulse pressure decreased from 58.8mm to 52.2 mm. Also in diabetic patients (21% of the cohort), further reduction of systolic blood pressure values could be achieved (mean before 150 mm, after 133), wherein the initial differences compared to patients without diabetes had disappeared. The pulse rate also changed from 75 b/min to 68 b/min under the FDC. Conclusion: These study results clearly show that the FDC leads to excellent patient adherence and therefore may result in better blood pressure control. Blood pressure control is crucial in the risk reduction of cardiovascular events. The key limitation of this study is that the study design does not allow a direct comparison of patient adherence under the free and the fixed-dose combination.
引用
收藏
页码:875 / 881
页数:7
相关论文
共 50 条
  • [41] Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review (vol 14, 1156655, 2024)
    Dat, Truong Van
    Tu, Vo Linh
    Thu, Le Nguyen Anh
    Quang, Nguyen Nhat Anh
    Binh, Van
    Nga, Nguyen Thi Quynh
    Loc, Duong Hoang
    Nguyen, Tran Thi Hong
    Tam, Dao Ngoc Hien
    Huynh, Hong-Han
    Trung, Tran Dinh
    Do, Uyen
    Phat, Nguyen Tuan
    Hung, Dang The
    Nguyen, Quang-Hien
    Yen, Nguyen Thi Hai
    Minh, Le Huu Nhat
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension
    Sander, Gary E.
    Fernandez, Camilo
    Giles, Thomas D.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2016, 14 (05) : 563 - 572
  • [43] Effect of a fixed-dose perindopril and amlodipine combination on intrarenal hemodynamic and kidney functional parameters in patients with essential hypertension
    Iskenderov, B. G.
    Budagovskaya, Z. M.
    Sisina, O. N.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (05) : 78 - 83
  • [44] The effect of fixed-dose combination of valsartan and amlodipine on nighttime blood pressure in patients with non-dipper hypertension
    Erdogan, Dogan
    Icli, Atilla
    Aksoy, Fatih
    Akcay, Salaheddin
    Yucel, Habil
    Ersoy, Ibrahim
    Ozaydin, Mehmet
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2016, 44 (05): : 404 - 413
  • [45] LEFT VENTRICULAR-ARTERIAL COUPLING CHANGES DURING TREATMENT WITH BISOPROLOL MONOTHERAPY AND BISOPROLOL/AMLODIPINE FIXED DOSE COMBINATION
    Bogomaz, Anna
    Kotovskaya, Yulia
    Kobalava, Zhanna
    JOURNAL OF HYPERTENSION, 2016, 34 : E449 - E450
  • [46] Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension
    Rakugi, Hiromi
    Tsuchihashi, Takuya
    Shimada, Kazuyuki
    Numaguchi, Hirotaka
    Nishida, Chisato
    Yamaguchi, Hiroya
    Shirakawa, Masayoshi
    Azuma, Kyoichi
    Fujita, Kenji P.
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2015, 37 (03) : 260 - 266
  • [47] Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD
    Chrysant, Steven G.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (09) : 1115 - 1124
  • [48] Fixed-dose combination therapy in the treatment of hypertension: Ready for prime time
    Basile, Jan N.
    SOUTHERN MEDICAL JOURNAL, 2007, 100 (04) : 343 - 344
  • [49] FIXED-DOSE COMBINATION MEDICATIONS FOR THE TREATMENT OF HYPERTENSION - A CRITICAL-REVIEW
    OSTER, JR
    EPSTEIN, M
    JOURNAL OF CLINICAL HYPERTENSION, 1987, 3 (03): : 278 - 293
  • [50] A FIXED-DOSE PRAZOSIN-POLYTHIAZIDE COMBINATION (MINIZIDE) IN THE TREATMENT OF HYPERTENSION
    MABADEJE, AFB
    OKUWOBI, BO
    GEORGE, BO
    ODUTOLA, TA
    ADEOLA, RF
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1981, 30 (05): : 718 - 730